Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
6208- CUR,    Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial
- Trial, Nor, NA
*memory↑, *Aβ↓, *tau↓,
3577- CUR,    Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
- Trial, AD, NA
*cognitive∅, *BioAv↑,
6238- CUSP9,    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3
- Trial, GBM, NA
toxicity↓, TrxR↓, ROS↓, TumCI↓, TumCMig↓, TumCA↓, MMP2↓, MMP9↓, COX2/PTGS2↓, ALDH↓, TumAuto↑, P-gp/ABCB1↓, eff↑,
6241- CUSP9,    RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4
- Trial, GBM, NA
eff↑,
6262- Cyste,    A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety
- Trial, Nor, NA
*eff↑,
6260- Cyste,    A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
- Trial, Nor, NA
*toxicity?,
6592- DAS,    Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- Trial, CML, NA
Dose↝, other↝, OS↑,
6679- DCA,    GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial
- Trial, Melanoma, NA
PDK1 / PDPK1↓, Half-Life↝, eff↑, NP/CIPN↑, Dose↝, Half-Life↝,
6678- DCA,  Cisplatin,    Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
- Trial, HNSCC, NA
PDK1 / PDPK1↓, OS∅, lactateProd↓, toxicity↝, FAO↑,
6749- DHA,    The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
- Trial, BC, NA
*IFN-γ↑, *TNF-α↑, Imm↑,
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, *NLR↓, eff↑, *IL4↑, *IL10↑, *IFN-γ↑, *TNF-α↑, Imm↑, eff↑, TumW↓,
6751- DHA,    Exploratory outcomes of the DHA WIN randomized controlled trial: Supplementing women with docosahexaenoic acid did not reduce the impact of neoadjuvant breast cancer chemotherapy on quality of life or exercise behaviour
- Trial, BC, NA
QoL∅,
6752- DHA,    A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
- Trial, BC, NA
TNF-α∅, IL1β∅, COX2/PTGS2∅,
6754- DHA,    Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
- Trial, AD, NA
*DHA↑, *eff↝, *BrainVol∅, *cognitive∅,
6755- DHA,    Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia
- Trial, AD, NA
*other↝,
6758- DHA,  Chemo,    Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
- Trial, BC, NA
ChemoSen↑, selectivity↑, ROS↑, *toxicity↓, Dose↝,
6760- DHA,    Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
- Trial, Nor, NA
*BP↓, *eff↝,
6761- DHA,    Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women
- Trial, Nor, NA
*BP↓,
6711- dietF,    Gut-microbiota-targeted diets modulate human immune status
- Trial, Nor, NA
*GutMicro↑, *Inflam↓, *Imm↑, *Obesity↓, *AntiDiabetic↑, *AntiCan↑, *cardioP↑, *IL6↓, *IL10↓, *IL12↓,
1848- dietFMD,  Chemo,    Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
- Trial, BC, NA
ChemoSideEff↓, ChemoSen↑, eff↑,
1855- dietFMD,    Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study
- Trial, NA, NA
ChemoSideEff↓, QoL↑, IGF-1↓, Insulin↓,
1862- dietFMD,    Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
- Trial, Var, NA
OS↑,
1842- dietFMD,    Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment
- Trial, Var, NA
Strength∅, Weight∅, IGF-1↓, IGFBP3↑, IGFBP1↑, eff↑,
1841- dietFMD,    Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
- Trial, Var, NA
BG↓, AntiCan↑, IFN-γ↑, eff↑, Dose↝, CD14↓, IGF-1↓, IGFR↓, CD8+↑, NK cell↑,
5193- dietMet,  Rad,    A Phase I Trial of a Methionine Restricted Diet with Concurrent Radiation Therapy
- Trial, Var, NA
toxicity↝, other↝,
2165- dietP,  SFN,    Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study
- Trial, PC, NA
Dose↝, OS↑, eff↝,
2160- dietP,    Dietary proteins and protein sources and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study
- Trial, Heart, NA
Risk↓,
2154- dietP,  Ex,    American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)
- Trial, Colon, NA
OS↑,
6729- Dipy,    Dipyridamole prevents triple-negative breast-cancer progression
- Trial, BC, MDA-MB-231
TumCG↓, TumMeta↑, β-catenin/ZEB1↓, *AntiAg↑, TumCCA↑, Wnt↓, NF-kB↓,
6737- Dipy,    Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 (TOLD)
- Trial, Nor, NA
*AntiAg↑, *Inflam↓, *AntiThr↑, *Dose↝,
6265- DL,    Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee
- Trial, Var, NA
toxicity↓, Dose↑, OS↑,
6266- DL,    Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer
- Trial, BC, NA
chemoPv↑, cycD1/CCND1↓, IGF-1↑, TumCCA↑, TumCP↓,
6279- DL,    Human breast tissue disposition and bioactivity of limonene in women with early stage breast cancer
- Trial, BC, NA
chemoPv↑, cycD1/CCND1↓,
4917- DSF,  Chemo,  Cu,    Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
- Trial, GBM, NA
OS∅, toxicity↑,
6803- EA,    Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial
- Trial, IBD, NA
*Dose↝, *MDA↓, *TAC↑, *CRP↓, *IL6↓, *Inflam↓, *ROS↓, *QoL↑, *toxicity↓,
6612- Ech,    Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial
- Trial, Nor, NA
*Imm↑, Dose↝, eff↑,
6603- Ech,  doxoR,    The effect of Echinacea purpurea on the pharmacokinetics of docetaxel
- Trial, Var, NA
other∅, other↝, Imm↑, CYP3A4⇅, other↑,
7225- EGb 761,    Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
- Trial, AD, NA
*cognitive↑, *Dose↝, *Dose↝,
7232- EGb 761,    Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial
- Trial, AD, NA
*cognitive↑, *toxicity↓,
7241- EGb 761,  ASA,    Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial
- Trial, Nor, NA
*Dose↝, *AntiAg∅,
653- EGCG,    Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)
- Trial, CLL, NA
ALC↓, Remission↑,
2562- EGCG,    Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial
- Trial, NA, NA
AntiAg↑, other↝,
6790- EPA,    Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia
- Trial, Lung, NA
*Dose↝, Weight↑, cachexia↓, OS∅,
6792- EPA,    Effect of Eicosapentaenoic Acid on Body Composition and Inflammation Markers in Patients with Head and Neck Squamous Cell Cancer from a Public Hospital in Mexico
- Trial, HNSCC, NA
Dose↝, *IL1β↓, *IL6↓, *TNF-α↓, *IFN-γ↓, QoL↑,
5234- Ex,    Intense Walking Exercise Affects Serum IGF-1 and IGFBP3
- Trial, Nor, NA
*IGF-1↓, *IGFBP3↓,
5235- Ex,    Effect of Low-Intensity Aerobic Exercise on Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-Binding Proteins in Healthy Men
- Trial, Nor, NA
Insulin↓, IGF-1↓, IGFBP1↑, eff↑,
5230- Ex,    Effects of an acute maximal exercise bout on serum insulin-like growth factor-1 in adults with MDD
- Trial, Nor, NA
*IGF-1↑, Dose↝,
5063- Ex,    A randomized controlled trial on the efficacy of supervised exercise training in reducing IGF-1 levels in breast cancer survivors of the Movis’ cohort
- Trial, BC, NA
IGF-1↓, IGFBP3↓,
4137- Ex,    The impact of exercise on patients with dementia
- Trial, AD, NA
*Strength↑, *QoL↑, *cognitive∅,
4070- FA,    Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial
- Trial, AD, NA
*cognitive↑, *Aβ↓, *TNF-α↓, *Inflam↓,

Showing Research Papers: 101 to 150 of 435
Prev Page 3 of 9 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 435

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

2/16-OHE1↑, 1,   8-oxo-dG↓, 1,   ADCY4↑, 1,   AEs∅, 1,   APG↓, 2,   CIT↓, 1,   CR↑, 2,   DCR↑, 3,   DCR↝, 1,   ENL↑, 1,   IGF-2R↑, 1,   Ingr↑, 1,   JAG1↑, 1,   LC↑, 1,   mal↓, 1,   miR-106b↓, 1,   Mucositis↓, 4,   Nausea↓, 4,   Nausea∅, 2,   NEU1↑, 1,   NLR↓, 1,   ORR↑, 3,   ORR∅, 1,   PC↑, 3,   PFS↑, 4,   PFS∅, 1,   PGI2↓, 1,   RBC↑, 3,   RFS↑, 1,   TTP↑, 1,   UFR↑, 1,   Vomit↓, 4,   Vomit∅, 2,   WBC↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Bil∅, 1,   Copper↓, 2,   CoQ10↑, 1,   GSH↓, 1,   MDA↓, 1,   ROS↓, 3,   ROS↑, 5,   ROS↝, 2,   SOD↑, 1,   TrxR↓, 1,   VitC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

selm↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

BCR-ABL↓, 1,   Insulin↓, 2,   MPT↑, 1,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   BUN↓, 1,   CYP3A4⇅, 1,   FAO↑, 1,   lactateProd↓, 1,   PDK1 / PDPK1↓, 2,   PPARγ↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 6,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Cyt‑c↝, 1,   IAP1↓, 1,   Mcl-1↓, 3,   Myc↓, 1,   NOXA↑, 1,   PUMA↑, 1,   survivin↓, 1,   TRPV1↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-30a-5p↑, 1,   other?, 1,   other↓, 4,   other↑, 6,   other↝, 18,   other∅, 3,   SD↑, 4,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

NKX3.1↓, 1,   P53↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 2,   P21↑, 3,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CSCs↓, 2,   HDAC↓, 4,   HH↓, 3,   HH∅, 1,   IGF-1↓, 7,   IGF-1↑, 1,   IGFBP1↑, 2,   IGFBP3↓, 1,   IGFBP3↑, 1,   IGFR↓, 1,   NOTCH3↑, 1,   PI3K↓, 1,   PTEN↑, 2,   Smo↓, 1,   TumCG↓, 7,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AntiAg↑, 1,   AntiAg↝, 1,   AntiAg∅, 1,   Ca+2↓, 1,   Ca+2↑, 1,   GLI3↓, 1,   Ki-67↓, 6,   miR-19b↓, 1,   miR-29b↑, 1,   MMP2↓, 1,   MMP9↓, 2,   MMP9:TIMP1↑, 1,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   TumCA↓, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 9,   TumMeta↓, 1,   TumMeta↑, 1,   Twist↓, 1,   Vim↓, 1,   ZO-1↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 8,   angioG∅, 1,   EGFR↓, 3,   Endoglin↓, 1,   Hif1a↓, 1,   VEGF↓, 3,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,   P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↓, 1,   CD25+↓, 1,   CD4+↓, 1,   CD4+↑, 1,   cellSen?, 1,   COX2/PTGS2↓, 4,   COX2/PTGS2∅, 1,   CRP↓, 2,   FoxP3+↓, 1,   GM-CSF↓, 1,   IFN-γ↑, 1,   IL10↓, 1,   IL12↓, 1,   IL18↑, 1,   IL1β↓, 1,   IL1β∅, 1,   IL22↓, 1,   IL6↓, 4,   Imm↑, 11,   INF-γ↝, 1,   Inflam↓, 7,   LIF↑, 1,   MCP1/CCL2↓, 1,   Neut↓, 1,   Neut↑, 2,   NF-kB↓, 2,   NK cell↑, 4,   PDT+↓, 1,   PGE2↓, 2,   PSA↓, 10,   T-Cell↑, 1,   TNF-α↓, 1,   TNF-α∅, 1,   VitD↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   AR↝, 1,   DHT↓, 1,   EstroRS/ERS↑, 1,   testos↓, 1,   testos∅, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 9,   BioAv↝, 8,   BioEnh↑, 1,   ChemoSen↑, 6,   ChemoSen∅, 1,   CYP1A2↑, 1,   Dose?, 2,   Dose↓, 3,   Dose↑, 7,   Dose↝, 117,   Dose∅, 4,   eff↓, 2,   eff↑, 42,   eff↝, 6,   eff∅, 7,   Half-Life↑, 1,   Half-Life↝, 6,   RadioS↑, 4,   selectivity↑, 5,   TET2↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALC↓, 1,   AR↓, 2,   AR↝, 1,   AST↓, 2,   BG↓, 1,   Bil∅, 1,   CA125↓, 1,   CA125∅, 1,   CA19-9↓, 1,   CEC↝, 1,   creat↓, 1,   CRP↓, 2,   CTC↓, 1,   EGFR↓, 3,   EstroRS/ERS↑, 1,   GutMicro↑, 1,   HemoG↑, 1,   IL6↓, 4,   Ki-67↓, 6,   Myc↓, 1,   PSA↓, 10,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 6,   antiNeop↑, 1,   AntiTum↑, 3,   AntiTum∅, 1,   cachexia↓, 1,   cardioP↑, 3,   CardioT↑, 1,   CardioT↝, 1,   chemoP↑, 6,   chemoP∅, 1,   chemoPv↑, 5,   ChemoSideEff↓, 2,   fatigue↓, 3,   hepatoP↓, 1,   hepatoP↑, 2,   memory↑, 1,   NP/CIPN↓, 2,   NP/CIPN↑, 3,   Obesity↓, 1,   OS?, 1,   OS↑, 48,   OS↝, 1,   OS∅, 9,   Pain↓, 8,   QoL↑, 16,   QoL∅, 3,   radioP?, 1,   radioP↑, 5,   radioP↝, 1,   Remission↑, 3,   Risk↓, 13,   Risk↑, 2,   Risk↝, 2,   Risk∅, 4,   stomatitis↓, 1,   Strength↑, 1,   Strength∅, 1,   toxicity↓, 25,   toxicity↑, 1,   toxicity↝, 19,   toxicity∅, 1,   TumVol↓, 4,   TumW↓, 1,   Weight↑, 5,   Weight∅, 1,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 3,   Diar↓, 1,   Diar⇅, 1,   Inf↓, 4,   Sepsis↓, 1,  
Total Targets: 277

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

12-HETE↓, 1,   2/16-OHE1↑, 1,   5-HETE↓, 1,   AcOH↑, 2,   AntiBio↑, 2,   BDI↓, 1,   Buty↑, 3,   CCr / CrCl↓, 1,   CCr / CrCl∅, 1,   Eic↓, 1,   END↑, 1,   ENL↑, 1,   Eos↓, 1,   FEV1↑, 2,   FFA/NEFA↝, 1,   HRV↑, 1,   IgE↓, 1,   Ingr↝, 1,   IPSS↓, 1,   Learn↑, 1,   NLR↓, 1,   NMSS↓, 1,   PA↑, 2,   PCO↓, 1,   PEF↑, 1,   rHR↓, 1,   RT↓, 2,   SCFAs↑, 3,   SCFAs∅, 1,   Stress↓, 4,   Tinn↓, 1,   TMAO∅, 1,   UFR↑, 1,   UPDRS↓, 1,   UPDRSIII∅, 1,   UR↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 2,   antiOx↑, 11,   Bil↓, 2,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 5,   HDL↓, 2,   HDL↑, 4,   HO-1↑, 1,   Iron↓, 1,   lipid-P↓, 2,   MDA↓, 4,   MDA↑, 1,   MPOD↑, 2,   NRF2↑, 2,   ROS↓, 16,   SAM-e↓, 1,   SOD↑, 3,   TAC↑, 3,   TBARS↓, 1,   uricA↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↑, 1,   mtDam↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   adiP↑, 1,   ALAT↓, 3,   ALAT∅, 1,   AMPK↑, 1,   CRM↑, 1,   DHA↑, 2,   glucose∅, 1,   KeyT↝, 1,   lactateProd↓, 1,   LDH↓, 3,   LDL↓, 9,   NH3↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3↓, 1,   CK2↓, 1,   p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 2,   AntiThr↑, 3,   other?, 3,   other↓, 3,   other↑, 16,   other↝, 14,   other∅, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNArepair↑, 1,   DNMT3A↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Choline↑, 1,   Diff↝, 1,   EP2↑, 1,   HDAC3↓, 1,   IGF-1↓, 1,   IGF-1↑, 1,   IGFBP3↓, 1,   NOTCH↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 4,   AntiAg∅, 1,   MMP9↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   TXA2↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   COX1↓, 1,   CRP↓, 4,   IFN-γ↓, 1,   IFN-γ↑, 3,   IL1↓, 1,   IL10↓, 1,   IL10↑, 1,   IL10∅, 1,   IL12↓, 1,   IL17∅, 1,   IL1β↓, 5,   IL4↑, 1,   IL4∅, 1,   IL6↓, 9,   IL8↓, 1,   Imm↑, 5,   Inflam↓, 23,   MCP1/CCL2↓, 1,   MCP1/CCL2↝, 1,   NF-kB↓, 1,   NK cell↑, 3,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 8,   TNF-α↑, 3,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 3,   AChE↓, 4,   BDNF↑, 7,   BDNF∅, 1,   BrainVol↑, 1,   BrainVol↝, 1,   BrainVol∅, 3,   GABA↑, 1,   tau↓, 3,   p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 10,   Aβ∅, 1,   BACE/β-secretase↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

cortisol↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 18,   BioAv↝, 12,   Dose?, 6,   Dose↓, 1,   Dose↑, 7,   Dose↝, 111,   eff↓, 1,   eff↑, 21,   eff↝, 7,   eff∅, 1,   Half-Life↓, 2,   Half-Life↑, 2,   Half-Life↝, 19,   P450↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 3,   ALAT∅, 1,   Albumin↑, 2,   ALP↓, 1,   AST↓, 1,   AST∅, 1,   Bil↓, 2,   BloodF↑, 3,   BMD↑, 1,   BP↓, 12,   BP∅, 1,   CRP↓, 4,   GutMicro↑, 6,   GutMicro∅, 1,   Hcy/homoC↓, 13,   Hcy/homoC↝, 1,   HemoG↑, 1,   hs-CRP↓, 1,   IL6↓, 9,   LDH↓, 3,   PSA↓, 1,   TG/TAG↓, 1,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 2,   AntiDiabetic↑, 2,   AntiTum↑, 3,   ANXi↓, 2,   cardioP↑, 5,   chemoP↑, 3,   cognitive?, 1,   cognitive↓, 1,   cognitive↑, 68,   cognitive↝, 2,   cognitive∅, 12,   fatigue↓, 2,   GFR↓, 1,   GFR∅, 1,   hepatoP↑, 5,   memory↑, 23,   memory∅, 1,   Mood↑, 7,   motorD↑, 9,   MusCon↓, 1,   neuroP↑, 12,   Obesity↓, 2,   Pain↓, 8,   QoL?, 1,   QoL↑, 10,   RenoP↑, 3,   Risk↓, 5,   Risk↑, 2,   Risk↝, 1,   Sleep↑, 6,   Strength↑, 4,   toxicity?, 1,   toxicity↓, 31,   toxicity↑, 1,   toxicity↝, 3,   toxicity∅, 7,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 2,   AntiViral↑, 4,   Bacteria↓, 2,  
Total Targets: 227

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page